Full-Time

Manager People Analytics & Insights

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA + 1 more

More locations: Boca Raton, FL, USA

In Person

On-site in King of Prussia, PA or Boca Raton, FL; no remote work.

Bachelor's, Master's, PhD

Category
People & HR (1)
Required Skills
Power BI
Python
Regression
R
Workday HRIS
SQL
Machine Learning
SAP Products
Tableau
Data Governance
Excel/Numbers/Sheets

Get referred to CSL

See people who can refer or advise you

Requirements
  • Experience: 8–12 years of experience in data analytics, people analytics, or a closely related discipline, with demonstrated experience owning analytical domains and driving insight-led decisions at a senior level in complex organizations.
  • Education: Degree-level qualification (or equivalent) in Data Analytics, Statistics, Economics, Organizational Psychology, Human Resources, or a related field. Postgraduate qualification or equivalent depth of practice is an advantage.
  • Technical Depth: Expert proficiency in BI tools (e.g. Power BI, Tableau) and Excel; advanced SQL; strong working proficiency in Python or R, including applying statistical or predictive methods to workforce data. Actively uses AI tools to enhance the quality and efficiency of analytical work.
  • Methodological Range: Able to design as well as apply analytical methods - including regression modelling, clustering, attrition prediction, or scenario modelling - and judge which approach is right for the problem, not just the tool at hand.
  • Framework & Standards Design: Demonstrated ability to design metrics frameworks, define analytical standards, or build scalable reporting infrastructure that others can work to.
  • HR Systems & Data Governance: Deep familiarity with HR data platforms (e.g. Workday, SAP SuccessFactors), data structures, and governance considerations, including multi-country and GDPR complexity.
  • Influence & Communication: Proven ability to shape how senior stakeholders think, not just reporting findings, but persuading, reframing, and leading discussions with credibility and composure under challenge.
  • Autonomy: Consistently works independently on ambiguous, high-stakes problems. Comfortable operating where the question is unclear, the data is imperfect, and the answer matters.
Responsibilities
  • Domain Ownership: Sets the analytical agenda of Talent Acquisition and Talent Development, defining relevant metrics, and ensuring outputs are consistently high quality, strategically relevant, and aligned to organizational priorities.
  • Complex & Ambiguous Analysis: Lead end-to-end analysis of complex problems, independently framing the question, selecting or developing the appropriate methodology, and delivering findings that meaningfully shift understanding or decision-making.
  • Stakeholder Influence: Engage senior HR and business stakeholders not just to explain findings, but to shape how they think about problems, influencing approach and direction.
  • Insight Narrative & Recommendations: Develop well-reasoned, evidence-based recommendations.
  • Data Quality & Governance Standards: Take accountability for the integrity and governance of people data within the domain, driving resolution across systems and process owners and contributing to enterprise-wide data standards.
  • Informal Leadership: Provide ongoing coaching and quality review for junior analysts, reviewing outputs, developing analytical capability, and raising team standards through day-to-day collaboration.
  • Innovation & Continuous Improvement: Proactively identify where existing approaches, models, or processes are insufficient and develop new ones, building new analytical capabilities where gaps exist.
  • Benchmarking & External Perspectives: Lead benchmarking and external research initiatives, interpreting comparative data in context and synthesizing external trends into actionable implications for the organization.
Desired Qualifications
  • Advanced Analytics in a Workforce Context: Hands-on experience applying predictive or machine learning techniques to people data - attrition modelling, skills clustering, internal mobility analysis, or similar.
  • Cross-Domain People Analytics: Experience spanning more than one analytics domain - e.g. engagement, succession planning, workforce planning, and DEI - with the ability to connect insights across them.
  • Global & Multi-Jurisdictional Data: Experience managing and interpreting datasets across multiple geographies, including navigating data privacy constraints.
  • Consulting or Embedded Advisory Experience: Background in a consulting environment or internal advisory role, with experience leading workstreams, managing stakeholder expectations, and delivering under defined accountability.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Germany approved HEMGENIX reimbursement on 2 April 2025, unlocking broader European commercialization.
  • CSL completed Austria and Denmark HEMGENIX launches in 2025, expanding revenue conversion.
  • CSL's November 2025 VarmX option targets a 2029 launch in urgent anticoagulant reversal.

What critics are saying

  • CSL cut up to 3,000 jobs in August 2025, signaling persistent margin stress.
  • The Pentagon ended mandatory flu shots in April 2026, pressuring Seqirus demand.
  • A failed VarmX Phase 3 program would waste CSL's US$117 million upfront and delay 2029 growth.

What makes CSL unique

  • CSL dominates plasma-derived therapies, built on global donor collection and manufacturing scale.
  • HEMGENIX proved durable four-year efficacy, strengthening CSL's premium hemophilia franchise.
  • CSL still owns rare-disease and vaccines expertise across Behring, Seqirus, and Vifor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

StockTitan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.